摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(6aR,8R,9R,9aS)-8-(6-amino-2-chloro-9H-purin-9-yl)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-9-ol | 111556-90-2

中文名称
——
中文别名
——
英文名称
(6aR,8R,9R,9aS)-8-(6-amino-2-chloro-9H-purin-9-yl)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-9-ol
英文别名
(6aR,8R,9R,9aS)-8-(6-amino-2-chloropurin-9-yl)-2,2,4,4-tetra(propan-2-yl)-6a,8,9,9a-tetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-9-ol
(6aR,8R,9R,9aS)-8-(6-amino-2-chloro-9H-purin-9-yl)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-9-ol化学式
CAS
111556-90-2
化学式
C22H38ClN5O5Si2
mdl
——
分子量
544.198
InChiKey
WQJVQPBOCTVQQD-QTQZEZTPSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    579.8±60.0 °C(Predicted)
  • 密度:
    1.36±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.28
  • 重原子数:
    35
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.77
  • 拓扑面积:
    127
  • 氢给体数:
    2
  • 氢受体数:
    9

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS D'ÉCTONUCLÉOTIDASE ET LEURS MÉTHODES D'UTILISATION
    申请人:CALITHERA BIOSCIENCES INC
    公开号:WO2018119284A1
    公开(公告)日:2018-06-28
    The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    这项发明涉及新颖的杂环化合物及其制药制剂。该发明还涉及使用该发明的新颖杂环化合物治疗或预防癌症的方法。
  • ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF
    申请人:Chen Lijing
    公开号:US20180072742A1
    公开(公告)日:2018-03-15
    The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    该发明涉及新颖的杂环化合物及其药物制剂。该发明还涉及使用该新颖杂环化合物治疗或预防癌症的方法。
  • Synthesis of Nucleosides and Deoxynucleosides via Gold(I)-Catalyzed <i>N</i>-Glycosylation of Glycosyl (<i>Z</i>)-Ynenoates
    作者:Rongkun Liu、Yan Chen、Jibin Zheng、Lvfeng Zhang、Tong Xu、Peng Xu、You Yang
    DOI:10.1021/acs.orglett.2c03964
    日期:2022.12.30
    with purines was found to be very effective for regioselective synthesis of pyranosyl N9 purine nucleosides. Based on the catalytic N-glycosylation approach, convenient synthesis of two 5′-deoxynucleosides drugs (capecitabine and galocitabine), four 2′-deoxynucleoside drugs (floxuridine, trifluridine, decitabine and cladribine), four 3′,5′-dideoxynucleoside analogues, and four 2′,5′-dideoxynucleoside
    核苷类似物广泛用作抗癌和抗病毒药物。在这里,我们开发了一种高效的金(I)催化的N-糖基化方法,用于以糖基(Z)-炔酸作为供体合成各种类型的核苷和脱氧核苷。31 个嘧啶核苷和 8 个嘌呤核苷的合成证明了N-糖基化方法的广泛范围。值得注意的是,金(I)催化的吡喃糖基(Z )-炔酸酯与嘌呤的N-糖基化被发现对于吡喃糖基N9嘌呤核苷的区域选择性合成非常有效。基于催化N-糖基化方法,方便合成两种5'-脱氧核苷药物(卡培他滨和加西他滨)、四种2'-脱氧核苷药物(氟尿苷、三氟尿苷、地西他滨和克拉屈滨)、四种3',5'-双脱氧核苷类似物,并集体获得了4个2',5'-双脱氧核苷类似物。
  • [EN] SYNTHESIS OF 2-ARALKYLOXYADENOSINES, 2-ALKOXYADENOSINES, AND THEIR ANALOGS<br/>[FR] SYNTHESE DE 2-ARALKYLOXYADENOSINES, 2-ALKOXYADENOSINES, ET LEURS ANALOGUES
    申请人:KING PHARMACEUTICALS RES & DEV
    公开号:WO2005033121A3
    公开(公告)日:2005-07-28
  • Synthesis and biological evaluations of certain 2-halo-2'-substituted derivatives of 9-.beta.-D-arabinofuranosyladenine
    作者:John A. Secrist、Anita T. Shortnacy、John A. Montgomery
    DOI:10.1021/jm00397a024
    日期:1988.2
    The synthesis of a series of 2-chloro- or 2-fluoro-9-(2-substituted-2-deoxy-beta-D-arabinofuranosyl)adenines (4g-n) is described. New compounds were prepared from either 2-chloroadenosine or 2-fluoroadenosine by first blocking the 3'- and 5'-hydroxyls as the tetraisopropyldisiloxane derivatives. Activation of O-2' by formation of a triflate followed by nucleophilic displacement allowed introduction of various groups in the proper configuration at C-2'. Fluoride ion treatment then produced the deblocked nucleosides. All of the new compounds were evaluated as cytotoxic agents against L1210 and H.Ep.-2 cells and as antiviral agents against herpes simplex viruses 1 and 2 and vaccinia virus in culture.
查看更多